CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...
Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for ...
The European Patent Office declared a patent owned by CureVac valid, after a challenge from drugmaker BioNTech, the company said on Thursday. U.S.-listed shares of Germany-based CureVac rose 11.8% in ...
Companies and inventors from around the world filed 199,264 patent applications at the European Patent Office (EPO) last year ...
CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...
Germany-headquartered CureVac (Nasdaq: CVAC) late Thursday announced that the European Patent Office (EPO) has confirmed the ...
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...
Lawmakers of the European Parliament’s Legal Affairs committee have demanded clarity from the European Commission on its ...
The European Patent Office’s latest report shows patent filings holding steady, with computer technology leading growth.
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...
MUNICH, March 31, 2025 /PRNewswire/ -- The European Patent Office (EPO) published its annual Patent Index 2024 today, revealing that a total of 199,264 European patent applications were filed last ...
March 27 (Reuters) - The European Patent Office declared a patent owned by CureVac (5CV.DE), opens new tab, valid, after a challenge from drugmaker BioNTech (22UAy.DE), opens new tab, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results